# Maurizio Scaltriti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maurizio-scaltriti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,380 |
| Field | PI3K/AKT/mTOR signaling in cancer |
| h-index | 75 |
| i10-index | 146 |
| Last Known Institution | AstraZeneca (Japan) |
| OpenAlex ID | https://openalex.org/A5002819777 |
| ORCID iD | https://orcid.org/0000-0002-5522-1447 |
| Works | 677 |

## Researcher papers

- [The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers](https://scholariq.org/papers/the-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers/)
- [PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer](https://scholariq.org/papers/pi3k-inhibition-results-in-enhanced-estrogen-receptor-function-and-dependence-in/)
- [HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers](https://scholariq.org/papers/her2-mediated-internalization-of-cytotoxic-agents-in-i-erbb2-i-amplified-or/)

## Researcher topics

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [AstraZeneca (Japan)](https://scholariq.org/institutions/astrazeneca-japan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.